Home › Peripheral Arterial Disease › Oklahoma › Oklahoma City
Peripheral Arterial Disease clinical trials in Oklahoma City, OK
4 studies for Peripheral Arterial Disease are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
RecruitingPhase 3
- Hightower Clinical, Oklahoma City
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
Recruiting
- O'Donoghue Research Building, University of Oklahoma Health Sciences Center, Oklahoma City
SELUTION4BTK Trial
Recruiting
- Hightower Clinical Research, Oklahoma City
The Effects of Diet and Exercise Interventions in Peripheral Artery Disease
Recruiting
- O'Donoghue Research Building, University of Oklahoma Health Sciences Center, Oklahoma City
About Peripheral Arterial Disease
Peripheral arterial disease (PAD) happens when there is a narrowing of the blood vessels outside of your heart. Learn about symptoms and treatment.
More about Peripheral Arterial Disease on MedlinePlus
Peripheral Arterial Disease trials in other cities
- Boston, MA10 studies
- Dallas, TX9 studies
- Cleveland, OH9 studies
- Chicago, IL9 studies
- Houston, TX8 studies
- Omaha, NE7 studies
- Gainesville, FL7 studies
- Miami, FL6 studies
- Nashville, TN6 studies
- Minneapolis, MN6 studies
- Detroit, MI6 studies
- Aurora, CO6 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer16 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Bladder Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.